Advertisement

 

 

Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age.

Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age.
Author Information (click to view)

Buckley LF, Rybak E, Aldemerdash A, Cheng JW, Fanikos J,


Buckley LF, Rybak E, Aldemerdash A, Cheng JW, Fanikos J, (click to view)

Buckley LF, Rybak E, Aldemerdash A, Cheng JW, Fanikos J,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Clinical cardiology 2016 Oct 7() doi 10.1002/clc.22591
Abstract

A growing number of patients with an indication for stroke prevention in atrial fibrillation have kidney-, age-, or weight-related alterations in pharmacokinetics that affect dosing of direct oral anticoagulants. Because these patients were excluded from or comprised a small number of patients in clinical trials, there is a lack of evidence to guide clinicians. As a consequence, many patients do not receive oral anticoagulation despite a high risk for atrial fibrillation-related stroke. Here, we present a review of direct oral anticoagulant pharmacokinetics and a review of the available clinical evidence in patients with weight-, kidney-, and age-related disease.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × three =

[ HIDE/SHOW ]